Developer docs
API playgroundTry for free, no card

Search company profiles

Oncology Ventures

Full company profile

uuid00007mp

Namestring
Oncology Ventures
Legal namestring
Oncology Ventures
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Oncology Ventures is a venture capital firm founded in 2021 by Ben Freeberg, a Stage 3a testicular cancer survivor, that invests in commercially validated healthcare data companies addressing fragmentation in U.S. cancer care. The firm targets startups across the oncology value chain, including early detection (mPATH, Gabbi), patient navigation and care coordination (CancerNavigator, OncoveryCare, Reimagine Care, Daymark Health), AI-powered treatment optimization and clinical workflow (Triomics, RISA Labs, Lumonus, Concr), specialty care delivery (Tono, NexCure for CAR-T in outpatient settings), research infrastructure (Ignite, SpotDoc), and precision oncology intelligence (BIOMAKERS). The fund's core technology is its investment thesis and LP network rather than a software product; the firm's primary "product" is capital, sector expertise, and distribution access to a network of cancer care institutions.

The firm operates a traditional venture fund revenue model, earning management fees and carried interest from limited partners. Fund I closed at $32 million in 2024 and Fund II closed oversubscribed at $62 million in April 2026, anchored by Texas Oncology, with limited partners collectively treating approximately one in three U.S. cancer patients. The team is lean (4 people) and includes the founder, a CFO, an executive assistant, and a venture associate sourced from Memorial Sloan Kettering and Flatiron Health. GTM is relationship-driven, with deal flow originating from the LP network, founder's personal network from his cancer journey, prior Optum Ventures and Thyme Care relationships, and earned media in healthcare/tech publications. The fund does not sell to end customers directly; portfolio companies' enterprise solutions are distributed through health systems, cancer centers, and life sciences organizations.

Short descriptiontext

Oncology Ventures is a venture capital firm founded in 2021 that invests in commercially validated healthcare data startups transforming U.S. cancer care delivery, with $94M in cumulative fund commitments anchored by major oncology institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, oncology investment, healthcare venture capital, cancer care startups, early-stage investing
Industry2 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAFAHAC
Oncology & Cancer Specialty Hospitals
Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Healthcare Investment
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management / Carry
TypeManaged Services
Description

Oncology Ventures generates returns through venture fund management, collecting management fees and carried interest from successful portfolio company exits. Fund II is a $62M oversubscribed fund nearly doubling the $32M Fund I.

pulse2.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Oncology Ventures is a venture capital firm that invests in commercially validated, data-driven healthcare startups addressing the biggest problems in cancer care. The firm manages dedicated oncology-focused funds (Fund I at $32M and Fund II at $62M) backed by institutional limited partners that include major U.S. cancer care institutions such as Texas Oncology, Moffitt Cancer Center, City of Hope, Fred Hutch Cancer Center, Atlantic Health, and Cardinal Health. The firm targets startups across early detection, patient navigation, AI-powered treatment optimization, value-based care delivery, and clinical workflow automation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Fund II at $62M oversubscribed, nearly doubling Fund I ($32M) and exceeding $50M target
+2 more records
Product and service2 records
1Oncology Ventures Fund I
CategoryVenture Capital Fund
2Oncology Ventures Fund II
CategoryVenture Capital Fund
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Oncology Ventures promotes Daymark Health's value-based oncology care model at conferences alongside the fund. Daymark Health raised $20M Series A to scale tech-enabled cancer care platform across the U.S.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Oncology Ventures announced investment in CancerNavigator, a platform combining real-time claims detection, evidence-based research engine mapping over 200,000 cancer-specific scenarios, and national provider suitability database to improve oncology routing decisions. One million Americans now have access through their health plans.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large venture firm with significant healthtech and biotech exposure, including AI-driven diagnostics and digital health. Comparable as a healthcare-active investor with much broader sector mandate than Oncology Ventures' specialist focus.

TypeBroad incumbent
Description

Major venture firm with dedicated Bio + Health fund investing across digital health, biotech, and care delivery. Comparable as a healthcare-active investor but operating at mega-fund scale and broader thesis than an oncology-focused specialist.

TypeBroad incumbent
Description

Large multi-stage venture firm with a significant healthcare practice (Health Assurance), investing across digital health, biotech, and care delivery. Comparable as a major healthcare investor but at much larger scale and broader mandate than Oncology Ventures.

TypeBroad incumbent
Description

Science and technology-focused venture firm with deep exposure to healthtech, biology, and frontier science including oncology-adjacent companies. Comparable as a thesis-led investor but with a broader science mandate than pure oncology focus.

TypeDirect peer
Description

Early-stage venture firm specializing in life sciences, biotechnology, and healthcare technology, with significant oncology exposure. Comparable as a deep, science-driven healthtech specialist.

TypeDirect peer
Description

Healthcare-focused venture firm that co-led Modicus Prime's round alongside Oncology Ventures. Highly comparable as a thesis-driven investor in healthcare technology and services, with similar LP base among provider systems.

TypeDirect peer
Description

Venture fund founded by Bill Maris (formerly Google Ventures) investing at the intersection of technology and biology, including oncology and AI-driven healthcare. Highly comparable as a thesis-driven, oncology-and-healthtech-focused specialist investor.

TypeDirect peer
Description

Healthcare and life sciences-focused venture firm backing data, diagnostics, and therapeutic companies. Comparable as a specialist investor with deep domain focus on healthcare innovation including oncology.

TypeDirect peer
Description

Healthcare-focused venture arm of Optum/UnitedHealth Group that invests in data and technology companies transforming care delivery. Most directly comparable given founder Ben Freeberg's prior investing role there and shared thesis around healthcare data infrastructure.

TypeBroad incumbent
Description

Alphabet's venture arm with active life sciences and digital health practice, including oncology investments. Comparable as a tech-forward healthcare investor but with a much broader sector mandate than Oncology Ventures.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment17 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncology Ventures

Venture Capital / Healthcare Investmentoncology.ventures

Oncology Ventures is a venture capital firm founded in 2021 that invests in commercially validated healthcare data startups transforming U.S. cancer care delivery, with $94M in cumulative fund commitments anchored by major oncology institutions.

What Oncology Ventures does

Oncology Ventures is a venture capital firm founded in 2021 by Ben Freeberg, a Stage 3a testicular cancer survivor, that invests in commercially validated healthcare data companies addressing fragmentation in U.S. cancer care. The firm targets startups across the oncology value chain, including early detection (mPATH, Gabbi), patient navigation and care coordination (CancerNavigator, OncoveryCare, Reimagine Care, Daymark Health), AI-powered treatment optimization and clinical workflow (Triomics, RISA Labs, Lumonus, Concr), specialty care delivery (Tono, NexCure for CAR-T in outpatient settings), research infrastructure (Ignite, SpotDoc), and precision oncology intelligence (BIOMAKERS). The fund's core technology is its investment thesis and LP network rather than a software product; the firm's primary "product" is capital, sector expertise, and distribution access to a network of cancer care institutions.

The firm operates a traditional venture fund revenue model, earning management fees and carried interest from limited partners. Fund I closed at $32 million in 2024 and Fund II closed oversubscribed at $62 million in April 2026, anchored by Texas Oncology, with limited partners collectively treating approximately one in three U.S. cancer patients. The team is lean (4 people) and includes the founder, a CFO, an executive assistant, and a venture associate sourced from Memorial Sloan Kettering and Flatiron Health. GTM is relationship-driven, with deal flow originating from the LP network, founder's personal network from his cancer journey, prior Optum Ventures and Thyme Care relationships, and earned media in healthcare/tech publications. The fund does not sell to end customers directly; portfolio companies' enterprise solutions are distributed through health systems, cancer centers, and life sciences organizations.

Oncology Ventures firmographics

Firmographics
Name
Oncology Ventures
Legal name
Oncology Ventures
Website
https://oncology.ventures
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Oncology Ventures is a venture capital firm founded in 2021 that invests in commercially validated healthcare data startups transforming U.S. cancer care delivery, with $94M in cumulative fund commitments anchored by major oncology institutions.
Ownership category
akta.pro rank

Oncology Ventures industry classification

Industry
Product category
Venture Capital / Healthcare Investment
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAFAHAC
Oncology & Cancer Specialty Hospitals
Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care

Keywords

  • Venture capital funding
  • Oncology investment
  • Healthcare venture capital
  • Cancer care startups
  • Early-stage investing

Where Oncology Ventures is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Oncology Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Fund Management / Carry: Oncology Ventures generates returns through venture fund management, collecting management fees and carried interest from successful portfolio company exits. Fund II is a $62M oversubscribed fund nearly doubling the $32M Fund I.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Oncology Ventures product offering

Product offering

Core offering

Oncology Ventures is a venture capital firm that invests in commercially validated, data-driven healthcare startups addressing the biggest problems in cancer care. The firm manages dedicated oncology-focused funds (Fund I at $32M and Fund II at $62M) backed by institutional limited partners that include major U.S. cancer care institutions such as Texas Oncology, Moffitt Cancer Center, City of Hope, Fred Hutch Cancer Center, Atlantic Health, and Cardinal Health. The firm targets startups across early detection, patient navigation, AI-powered treatment optimization, value-based care delivery, and clinical workflow automation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oncology Ventures Fund I
  • Oncology Ventures Fund II

Quantifiable outcome

  • Fund II at $62M oversubscribed, nearly doubling Fund I ($32M) and exceeding $50M target
  • +2 more outcomes

Companies that use Oncology Ventures

Customer profile

Segments1 record

Ideal customer profiles2 records

Oncology Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Oncology Ventures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Daymark HealthcoreStrategic or Co-development Partner · 1 May 2026Oncology Ventures promotes Daymark Health's value-based oncology care model at conferences alongside the fund. Daymark Health raised $20M Series A to scale tech-enabled cancer care platform across the U.S.
  • CancerNavigatorcoreStrategic or Co-development Partner · 1 February 2026Oncology Ventures announced investment in CancerNavigator, a platform combining real-time claims detection, evidence-based research engine mapping over 200,000 cancer-specific scenarios, and national provider suitability database to improve oncology routing decisions. One million Americans now have access through their health plans.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Oncology Ventures competitors and assessment

Company assessment

Broad incumbents

  • Khosla Ventures: Large venture firm with significant healthtech and biotech exposure, including AI-driven diagnostics and digital health. Comparable as a healthcare-active investor with much broader sector mandate than Oncology Ventures' specialist focus.
  • Andreessen Horowitz (a16z Bio + Health): Major venture firm with dedicated Bio + Health fund investing across digital health, biotech, and care delivery. Comparable as a healthcare-active investor but operating at mega-fund scale and broader thesis than an oncology-focused specialist.
  • General Catalyst: Large multi-stage venture firm with a significant healthcare practice (Health Assurance), investing across digital health, biotech, and care delivery. Comparable as a major healthcare investor but at much larger scale and broader mandate than Oncology Ventures.
  • Lux Capital: Science and technology-focused venture firm with deep exposure to healthtech, biology, and frontier science including oncology-adjacent companies. Comparable as a thesis-led investor but with a broader science mandate than pure oncology focus.
  • GV (Google Ventures): Alphabet's venture arm with active life sciences and digital health practice, including oncology investments. Comparable as a tech-forward healthcare investor but with a much broader sector mandate than Oncology Ventures.

Direct peers

  • ARCH Venture Partners: Early-stage venture firm specializing in life sciences, biotechnology, and healthcare technology, with significant oncology exposure. Comparable as a deep, science-driven healthtech specialist.
  • Frist Cressey Ventures: Healthcare-focused venture firm that co-led Modicus Prime's round alongside Oncology Ventures. Highly comparable as a thesis-driven investor in healthcare technology and services, with similar LP base among provider systems.
  • Section 32: Venture fund founded by Bill Maris (formerly Google Ventures) investing at the intersection of technology and biology, including oncology and AI-driven healthcare. Highly comparable as a thesis-driven, oncology-and-healthtech-focused specialist investor.
  • Foresite Capital: Healthcare and life sciences-focused venture firm backing data, diagnostics, and therapeutic companies. Comparable as a specialist investor with deep domain focus on healthcare innovation including oncology.
  • Optum Ventures: Healthcare-focused venture arm of Optum/UnitedHealth Group that invests in data and technology companies transforming care delivery. Most directly comparable given founder Ben Freeberg's prior investing role there and shared thesis around healthcare data infrastructure.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Oncology Ventures social profiles

Digital presence

Oncology Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncology Ventures leadership team

Management profile

Number of profiles

Profiles4 records

Oncology Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncology Ventures M&A and investment

M&A and investment

M&A

Investments17 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncology Ventures

What does Oncology Ventures do?

Oncology Ventures is a venture capital firm that invests in commercially validated, data-driven healthcare startups addressing the biggest problems in cancer care. The firm manages dedicated oncology-focused funds (Fund I at $32M and Fund II at $62M) backed by institutional limited partners that include major U.S. cancer care institutions such as Texas Oncology, Moffitt Cancer Center, City of Hope, Fred Hutch Cancer Center, Atlantic Health, and Cardinal Health. The firm targets startups across early detection, patient navigation, AI-powered treatment optimization, value-based care delivery, and clinical workflow automation.

Is Oncology Ventures a public or private company?

Oncology Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Oncology Ventures founded?

Oncology Ventures was founded in 2021. It employs 1 to 10 people.

Where is Oncology Ventures based?

Oncology Ventures is headquartered in New York, United States, in the North America region.

How does Oncology Ventures make money?

One revenue line is on record: fund Management / Carry.

Who are Oncology Ventures's main competitors?

Broad incumbents on record are Khosla Ventures, Andreessen Horowitz (a16z Bio + Health), General Catalyst, Lux Capital and GV (Google Ventures). Direct peers are ARCH Venture Partners, Frist Cressey Ventures, Section 32, Foresite Capital and Optum Ventures.

Does Oncology Ventures have an API?

No public API is recorded for Oncology Ventures.

What industry is Oncology Ventures in?

Oncology Ventures's product category is Venture Capital / Healthcare Investment. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAFAHAC, Oncology & Cancer Specialty Hospitals. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineTrusted by Leading Cancer Centers to Solve Oncology's Information Overload, Triomics Raises $22 million to Accelerate AdoptionTriomics raised $22 million in Series B financing led by Battery Ventures, bringing total funding to over $36 million. The company will use the capital to accelerate adoption across cancer centers and expand its AI platform for clinical workflows and trial matching.VC News DailyTriomics Inks $22M Series B FundingTriomics, an oncology AI company, raised $22 million in Series B financing led by Battery Ventures. The round brings total funding to over $36 million. The company's platform supports patient trial matching, pre-visit chart prep, and oncology data abstraction.FinSMEsTriomics Raises $22M in Series B FundingTriomics, a NYC-based oncology AI company, raised $22M in Series B funding led by Battery Ventures. The round brings total funding to over $36M, with participation from existing investors and strategic backers. The company will use the funds to accelerate adoption across health systems and oncology networks.Venture Capital Access OnlineModicus Prime Raises $8M to Enable AI Audit Readiness Across PharmaModicus Prime raised $4.5M in additional funding led by Frist Cressey Ventures, bringing total funding to $8M. The company's Trustworthy AI Compliance Software enables audit-ready AI systems across pharmaceutical companies, aiming to reduce costly quality control failures estimated at $50 billion annually.FinSMEsModicus Prime Raises Additional $4.5M in FundingModicus Prime, an Austin-based AI compliance platform provider, raised $4.5M in additional funding led by Frist Cressey Ventures. The round brings total funding to $8M, with backing from Silverton Partners and Oncology Ventures. The company will use the funds to enhance customer support and platform features for international pharmaceutical clients.Pulse 2.0Oncology Ventures: $62 Million Fund II Closes Oversubscribed, Nearly Double The Size Of Fund IOncology Ventures, an Austin-based venture capital firm focused on commercially validated cancer care startups, has closed an oversubscribed $62 million Fund II, nearly doubling its $32 million Fund I and exceeding its $50 million target. The fund is anchored by Texas Oncology alongside renewed backing from Moffitt Cancer Center, City of Hope, Atlantic Health, and Cardinal Health, with new limited partners including Fred Hutch Cancer Center, collectively treating one in three U.S. cancer patients. The firm, founded by Ben Freeberg who survived Stage 3a cancer, invests in the $225 billion oncology market growing at 12% annually, targeting infrastructure that bridges oncology breakthroughs with patient delivery.VcwireOncology Ventures Closes Fund II, at $62MOncology Ventures closed its $62M Fund II, anchored by Texas Oncology, Moffitt Cancer Center, City of Hope, Atlantic Health, Cardinal Health, and Fred Hutch. The Austin-based firm invests in cancer-care startups, with portfolio companies including Risa, IgniteData, Tono, and Concr.citybizOncology Ventures Closes $62 Million Second Fund Backed by Texas Oncology and Cancer Care InstitutionsOncology Ventures has closed a $62 million second fund focused on startups developing tools and services for cancer care delivery, nearly doubling the size of its inaugural $32 million fund and exceeding its $50 million target. The fund is anchored by Texas Oncology and includes limited partners Moffitt Cancer Center, City of Hope, Atlantic Health, Cardinal Health, and Fred Hutch Cancer Center. The firm invests in operational oncology infrastructure including patient navigation, research workflow, treatment coordination, and cost management, targeting the growing market as cancer care costs rise for employers, insurers, and health systems.Business Wire BlogOncology Ventures Announces Oversubscribed $62 Million Fund II to Accelerate the Future of Cancer CareOncology Ventures announced the close of its oversubscribed $62 million Fund II, nearly doubling the size of its $32 million Fund I and exceeding its $50 million target, with Texas Oncology serving as the anchor limited partner alongside returning investors Moffitt Cancer Center, City of Hope, Atlantic Health, and Cardinal Health, plus new partner Fred Hutch Cancer Center. The venture firm invests in oncology market startups and counts limited partners that collectively treat one in three U.S. cancer patients. Founder Ben Freeberg, a Stage 3a cancer survivor, cited that 1,700 people die of cancer daily in the U.S. with over 1,000 of those deaths potentially preventable through earlier detection and better treatment navigation.SubstackOncology Ventures: Announcing Oversubscribed $62M Fund II to Accelerate the Future of Cancer Care + Duolingo ComedyOncology Ventures closed its oversubscribed $62 million Fund II, nearly double its $32 million Fund I and surpassing its $50 million target. The fund invests in cancer care startups, with portfolio companies like Risa, IgniteData, Tono, and Concr showing measurable savings and survival improvements.